Optimal treatment for recurrent/metastatic head and neck cancer.
about
Recent developments in receptor tyrosine kinases targeted anticancer therapyCurrent role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinomaHER2 as a therapeutic target in head and neck squamous cell carcinomaTreatment of Elderly Patients with Squamous Cell Carcinoma of the Head and NeckFADD expression is associated with regional and distant metastasis in squamous cell carcinoma of the head and neckTelomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.Ultrasound-stimulated drug delivery for treatment of residual disease after incomplete resection of head and neck cancer.Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment responseInhibitory effect of Ginkgol C17:1 on the biological behavior of tumor cells.Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckRac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC)Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significanceTargeting cancer stem cell plasticity through modulation of epidermal growth factor and insulin-like growth factor receptor signaling in head and neck squamous cell cancer.Prognostic significance of SOX2 in head and neck cancer: a meta-analysis.Combined concurrent photodynamic and gold nanoshell loaded macrophage-mediated photothermal therapies: an in vitro study on squamous cell head and neck carcinoma.Salvage surgery for locoregional recurrences of advanced pharyngolaryngeal squamous cell carcinoma after organ preservation failure.Overexpression of EMMPRIN isoform 2 is associated with head and neck cancer metastasisLRIG1 as a potential novel marker for neoplastic transformation in ocular surface squamous neoplasiaDownregulation of Ras association domain family member 6 (RASSF6) underlies the treatment resistance of highly metastatic nasopharyngeal carcinoma cells.A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck.High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.(99m)Tc-3P-RGD2 molecular imaging targeting integrin α v β 3 in head and neck squamous cancer xenograftCetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimenPhotothermal enhancement of chemotherapy mediated by gold-silica nanoshell-loaded macrophages: in vitro squamous cell carcinoma study.Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancerAntiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck.Determinants for aggressive end-of-life care for oral cancer patients: a population-based study in an Asian country.Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinomaSecond-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol.Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy.A genetic view of laryngeal cancer heterogeneityAbsent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma.Palliative chemotherapy in head and neck squamous cell cancer - What is best in Indian population? A time without symptoms, treatment toxicity score based studyTreatment of recurrent metastatic head and neck cancer: focus on cetuximab.Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancersOptical imaging of head and neck squamous cell carcinoma in vivo using arginine-glycine-aspartic acid peptide conjugated near-infrared quantum dots
P2860
Q26751331-3EEA0322-4935-412C-BF5F-605FC574DF86Q26991953-31E35493-8E4F-4B4A-9ADE-EE3D2841EFB4Q27026178-3F616F7E-7B66-46A9-A399-1C78B8C6AE3FQ28076894-5679DAAB-B346-4E27-82DE-AB63C2E225FAQ28292670-7F5BDEA0-EEBA-43AC-BE03-7DADB7F44AC8Q30248577-ADC490E0-F732-435E-BC2E-B4D5B79A0F7FQ30415659-97F84600-CCBB-45D2-8F69-CC48EF2BE495Q31162700-16473DE7-CE60-4D56-886D-014D953E5C6AQ33598182-E8C13FFA-8ECE-44FA-82E8-C8E8263574B7Q33650470-A4C8F2EA-CC87-451E-9174-25CDDBE22FF7Q33682966-B2871B33-99C6-4A55-B162-0995026160F2Q34020601-23FE14C5-1179-4005-A28F-767E9C9934B8Q34109375-7634FED7-752B-49FC-9F76-1656B8403AB1Q35017036-19F82134-D423-4A08-856D-43FD237C3960Q35125492-9B46CE3F-CA57-452E-87D2-6B48631D436FQ35139352-768BF6C9-6BFB-48D0-AEFC-8D2E25A3F19DQ35140115-00787D80-B2BF-41C2-A9CF-FB69DB2C8128Q35141723-13EC528B-EC19-4E87-B9A6-2B18AE892409Q35207555-4AC67325-C303-46E8-9619-0B5EF3343490Q35238022-33201A75-FA44-485B-A428-76280E6DB57BQ35382232-5EA62450-85EF-4048-B90E-85FDDBA9BAC0Q35839942-79DC2108-5D9E-4BC1-989B-E9EA23CEA11CQ35888323-E6824768-258A-44C9-BFB0-5228F4E7761AQ35894552-2C77F8D6-7FE2-4D8C-8A29-331F8408469EQ35904558-544646C9-70CA-40BF-AE19-6F5C3FE1F600Q36005545-5E9840FB-E6F8-4975-81F7-9D973ACDF9AAQ36072292-EF18AD30-1DC3-4AE0-B77E-59787CE15D2BQ36153369-B65ACC13-E595-4DC0-B2C8-33518306318CQ36204962-0863566A-97BF-4EDC-B2A2-3E8BA91D3933Q36214744-DE545EFD-EA29-4540-AC43-FD9FCDC6456EQ36480951-189C7DAA-E757-4DB5-9640-45ADD05514A6Q36537456-651D11E4-9E23-4303-8B5D-F3EEC06AF5C4Q36972817-D29D9A72-29C5-40AA-A32A-D4131D44056DQ37022410-9369AE3A-E198-46E5-A111-64649BF0C23BQ37026177-AE333866-018A-412B-97B0-42FE3902BA42Q37218978-DC177EA6-4EA4-43D5-B038-1089211B4147Q37274307-FE5C279C-0063-4411-A8DB-D93E8B183D52Q37274810-4FEE237D-BC53-4C45-801C-5B00BE416752Q37346163-94B735BA-6A6F-4BF0-8E05-5BE7FB55FE2DQ37373182-34D62AE5-512F-49FE-B43E-9DFE7A8B2F08
P2860
Optimal treatment for recurrent/metastatic head and neck cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Optimal treatment for recurrent/metastatic head and neck cancer.
@en
Optimal treatment for recurrent/metastatic head and neck cancer.
@nl
type
label
Optimal treatment for recurrent/metastatic head and neck cancer.
@en
Optimal treatment for recurrent/metastatic head and neck cancer.
@nl
prefLabel
Optimal treatment for recurrent/metastatic head and neck cancer.
@en
Optimal treatment for recurrent/metastatic head and neck cancer.
@nl
P2860
P356
P1433
P1476
Optimal treatment for recurrent/metastatic head and neck cancer
@en
P2093
J B Vermorken
P2860
P304
P356
10.1093/ANNONC/MDQ453
P478
21 Suppl 7
P577
2010-10-01T00:00:00Z